MapLight Therapeutics Reports Strong Cash Position & Key Clinical Milestones, Including Two Phase 2 Readouts in Q3 2026

summarizeSummary

MapLight Therapeutics reported robust financial results for Q4 and full year 2025, highlighting a strong cash position expected to fund operations through 2027, alongside significant progress in its clinical pipeline with two Phase 2 topline results anticipated in Q3 2026 and a recent FDA Fast Track designation.

check_boxKey Events

• Strong Cash Position and Runway

  The company ended 2025 with $453.1 million in cash, cash equivalents, and investments, which is expected to fund operations through 2027, significantly de-risking future financing.

• Two Phase 2 Topline Results Expected in Q3 2026

  Topline results are anticipated for the Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia and the Phase 2 IRIS trial of ML-004 for autism spectrum disorder.

• FDA Fast Track Designation Received

  ML-007C-MA was granted Fast Track designation by the FDA in December 2025 for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis.

• Pipeline Expansion with ML-055

  The company expanded its pipeline with a next-generation M1/M4 muscarinic agonist program, ML-055, with candidate nomination expected in 2026.

auto_awesomeAnalysis

MapLight Therapeutics has reported a robust financial position with $453.1 million in cash, cash equivalents, and investments, providing a runway expected to fund operations through 2027. This significantly de-risks the company's near-term financing needs, a critical factor for clinical-stage biopharmaceutical companies. The company also announced multiple significant clinical catalysts, including topline results for two Phase 2 trials (ML-007C-MA for schizophrenia and ML-004 for autism spectrum disorder) expected in the third quarter of 2026. Additionally, ML-007C-MA received FDA Fast Track designation for Alzheimer's disease psychosis, which could accelerate its development and review process. While R&D and net losses increased, this is typical for a company advancing multiple clinical programs. The combination of a strong balance sheet and multiple near-term, high-impact clinical readouts positions the company for a potentially transformative year.